Oxford BioMedica
Discover Realise

Clinical trials

Oxford BioMedica is currently recruiting for clinical trials as detailed below. For further information, please visit the www.clinicaltrials.gov website or contact your doctor or primary healthcare professional.

If you are currently participating in one of our clinical trials and you have a medical emergency, please contact either your study centre or the Oxford BioMedica switchboard on +44 (0) 1865 783 000.

RetinoStat®

Wet age-related macular degeneration

In a Phase I dose escalation safety study of RetinoStat®, a lentiviral vector expressing endostatin and angiostatin, in patients with advanced neovascular age-related macular degeneration, the primary end points of safety and tolerability at 6 months post-surgery were met. The study protocol requires patients to be followed up to 48 weeks after dosing. After the last patient's 48 week follow-up visit in March 2015 the Company will be able to finalise the clinical study report and assess the final data and strategy thereafter.

ClinicalTrials.gov Identifier: NCT01301443
Principal Investigator: Professor Peter Campochiaro
Johns Hopkins University Hospital, School of Medicine
Wilmer Eye Institute, Department of Ophthalmology
719 Maumenee, 600 N.Wolfe Street
Baltimore, MD, 21287-9277, USA

StarGen

Stargardt disease

A Phase I/IIa dose escalation safety study of StarGen, administered to patients with Stargardt macular degeneration.

ClinicalTrials.gov identifier: NCT01367444
Principal Investigator: Professor David Wilson
Casey Eye Institute
Oregon Health & Science University
Portland, Oregon, 97239-3098, USA
Principal Investigator: Professor Jose-Alain Sahel
Centre Hospitalier Nationale d'Ophthalmologie des Quinze-Vingts
Paris, France, 75571

UshStat®

Retinitis pigmentosa associated with Usher syndrome type 1B

A Phase I/IIa dose escalation safety study of UshStat®, administered to patients with retinitis pigmentosa associated with Usher syndrome type 1B.

ClinicalTrials.gov identifier: NCT01505062
Principal Investigator (US): Professor Richard Weleber
Oregon Health and Science University
Casey Eye Institute
Portland, Oregon 97239-4197, USA

Trials being conducted by our partners:

TroVax®

Mesothelioma                     

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma (SKOPOS)
 
ClinicalTrials.gov ID: NCT01569919
Principal Investigator: Jason F Lester, FRCR, MRCP
Velindre Cancer Centre
Cardiff, South Wales, United Kingdom, CF14 2TL

TroVax®

Colorectal cancer

A pilot study to assess the effect of regulatory T-cell depletion on 5T4-containing MVA(TroVax®)vaccination in patients with inoperable metastatic colorectal cancer (TaCTiCC)
 
EudraCT Number: 2010-024380-41
Principal Investigator: Dr Andrew Godkin
Henry Wellcome Building
School of Medicine
Heath Park
Cardiff, CF14 4XN, United Kingdom

 

Facts

Working together

Inside and outside of our business the relationships we build are based on genuine respect


Novel products

Our product candidates have the potential to transform treatment landscapes